Mary Gleeson

1.2k total citations · 1 hit paper
31 papers, 651 citations indexed

About

Mary Gleeson is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mary Gleeson has authored 31 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Mary Gleeson's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protein Degradation and Inhibitors (6 papers). Mary Gleeson is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protein Degradation and Inhibitors (6 papers). Mary Gleeson collaborates with scholars based in United Kingdom, Australia and United States. Mary Gleeson's co-authors include David Cunningham, Franck Morschhauser, Emanuele Zucca, Sandy Amorim, Lionel Karlin, Patrice Herait, Florence Broussais, Thierry Façon, Anastasios Stathis and Gilles Salles and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Mary Gleeson

27 papers receiving 638 citations

Hit Papers

Bromodomain inhibitor OTX015 in patients with lymphoma or... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    2016 328 citations Sandy Amorim, Anastasios Stathis et al. The Lancet Haematology profile →

Peers

Mary Gleeson
Yutaka Shimazu Japan
Valentina d’Escamard United States
Adrienne M. Dorrance United States
G. Larkin United Kingdom
Amrita Goyal United States
Adipong Brickshawana United States
Sachin Malhotra United States
Wolfgang Peter Germany
Shuji Momose Japan
Kazuki Taoka Japan
Yutaka Shimazu Japan
Mary Gleeson
Citations per year, relative to Mary Gleeson Mary Gleeson (= 1×) peers Yutaka Shimazu

Countries citing papers authored by Mary Gleeson

Since Specialization
Citations

This map shows the geographic impact of Mary Gleeson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Gleeson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Gleeson more than expected).

Fields of papers citing papers by Mary Gleeson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Gleeson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Gleeson. The network helps show where Mary Gleeson may publish in the future.

Co-authorship network of co-authors of Mary Gleeson

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Gleeson. A scholar is included among the top collaborators of Mary Gleeson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Gleeson. Mary Gleeson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Gleeson, Mary, David Cunningham, Clare Peckitt, et al.. (2025). The role of PET/CT in peripheral T‐cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO‐T trial. British Journal of Haematology. 207(2). 407–416.
4.
Linton, Kim, Francesco Forconi, David Lewis, et al.. (2023). Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies. Hematological Oncology. 41(S2). 573–574. 4 indexed citations
5.
Sharma, Bhupinder, Vasiliki Michalarea, Mary Gleeson, et al.. (2023). Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital. Clinical Lymphoma Myeloma & Leukemia. 24(1). 48–54.
6.
Searle, Emma, Francesco Forconi, Kim Linton, et al.. (2023). Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies. Blood. 142(Supplement 1). 4473–4473. 23 indexed citations
7.
Amin, Faisal Mohammad & Mary Gleeson. (2022). Beyond CHOP: optimising frontline therapy in peripheral T-cell lymphoma. Annals of Palliative Medicine. 11(7). 2548–2552. 1 indexed citations
8.
Gleeson, Mary, Nicholas Counsell, David Cunningham, et al.. (2020). Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial. British Journal of Haematology. 192(6). 1015–1019. 12 indexed citations
9.
Michalarea, Vasiliki, Ryan Low, Amy A. Kirkwood, et al.. (2019). EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R‐GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES. Hematological Oncology. 37(S2). 425–426. 1 indexed citations
10.
Gleeson, Mary, Nicholas Counsell, David Cunningham, et al.. (2017). Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Annals of Oncology. 28(10). 2511–2516. 48 indexed citations
11.
Amorim, Sandy, Anastasios Stathis, Mary Gleeson, et al.. (2016). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. The Lancet Haematology. 3(4). e196–e204. 328 indexed citations breakdown →
12.
Barton, Sarah, Eliza A. Hawkes, David Cunningham, et al.. (2014). Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma. European Journal Of Haematology. 94(3). 219–226. 9 indexed citations
13.
Thiéblemont, Catherine, Anastasios Stathis, Giorgio Inghirami, et al.. (2014). A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. Blood. 124(21). 4417–4417. 6 indexed citations
14.
Gleeson, Mary, Aengus O’Marcaigh, Melanie Cotter, et al.. (2012). Retinal vasculopathy in autosomal dominant dyskeratosis congenita due to TINF2 mutation. British Journal of Haematology. 159(5). 498–498. 9 indexed citations
15.
O’Malley, C. D., Victoria Chia, Karla Lindquist, et al.. (2010). Detection Bias and the High Incidence of Diabetes After Breast Cancer Diagnosis. Annals of Epidemiology. 20(9). 691–692. 2 indexed citations
16.
Desmond, Ronan, et al.. (2009). Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL. American Journal of Hematology. 85(8). 607–607. 8 indexed citations
17.
O’Malley, C. D., Mark D. Danese, Karla Lindquist, et al.. (2009). Diabetes in elderly patients with breast cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database. Journal of Clinical Oncology. 27(15_suppl). 11050–11050. 3 indexed citations
18.
Jeannon, Jean‐Pierre, F. Calman, Mary Gleeson, et al.. (2008). Management of advanced parotid cancer. A systematic review. European Journal of Surgical Oncology. 35(9). 908–915. 49 indexed citations
19.
Bishop, Nicolette C., Andrew K. Blannin, Paula J. Robson, Neil P. Walsh, & Mary Gleeson. (1999). The effects of carbohydrate supplementation on immune responses to a soccer-specific exercise protocol. Journal of Sports Sciences. 17(10). 787–796. 58 indexed citations
20.
Gleeson, Mary. (1997). Telemedicine: threats and opportunities.. PubMed. 5(3). 14–14. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yutaka Shimazu Breakdown of academic impact, for papers by Valentina d’Escamard Breakdown of academic impact, for papers by Adrienne M. Dorrance Breakdown of academic impact, for papers by G. Larkin Breakdown of academic impact, for papers by Amrita Goyal Breakdown of academic impact, for papers by Adipong Brickshawana Breakdown of academic impact, for papers by Sachin Malhotra Breakdown of academic impact, for papers by Wolfgang Peter Breakdown of academic impact, for papers by Shuji Momose Breakdown of academic impact, for papers by Kazuki Taoka
Rankless by CCL
2026